WAICF
15.12.2022 14:31:37 CET | Business Wire | Press release
On February 9th to 11th, 2023, the city of Cannes, in south of France, will once again become the world's nerve center for Artificial Intelligence (AI) during the World AI Cannes Festival, the first global event dedicated exclusively to AI, to the tech leaders who are innovating in it, and to the economic, human and societal issues that will impact our lives in the near future.
A second edition with a rich program
The Festival 2023 edition will be composed of several thematic zones, allowing to discover artificial intelligence in all its faces. Each zone will host companies and AI players introducing their solutions and offering demonstrations and immersive experiences. For the second edition, the thematic zones will focus on the new applications of artificial intelligence in robotics, gaming, catering, sports and well-being.
This new edition will also see the attendance of some countries through international pavilions (Switzerland, Scandinavia, Italy, Korea, Israel, Canada). An opportunity for visitors to take a world tour of Artificial Intelligence and discover the startups that will disrupt the future of the Tech sector. The world's leading universities and the best researchers on Artificial Intelligence will also be present at the Festival.
First renowned speakers to be featured at WAICF 2023
With two months to go before its opening, the WAICF is announcing some of the first headliners among many national and international speakers, coming from professional circles, research or public authorities:
- Chad ARONSON, Global Head of Intelligent Automation COE, UBER,
- Divya DWIVEDI, Advocate, SUPREME COURT OF INDIA
- Oren ETZIONI, CEO, Allen Institute for AI,
- Lila IBRAHIM, Chief Operating Officer, DEEPMIND,
- Luc JULIA, Chief Scientific Officer, RENAULT,
- Yann LECUN, Vice-President and Chief AI Scientist, META AI,
- Alberto PRADO, Vice-President, Global Head of Digital & Partnership, R&D, UNILEVER
- Stuart RUSSEL, Professor of Computer Science and Michael H. Smith and Lotfi A. Zadeh Chair in Engineering, UNIVERSITY OF CALIFORNIA, BERKELEY
- Manuela VELOSO, Head, J. P. MORGAN CHASE AI RESEARCH
- Miriam VOGEL, President & CEO, EqualAI,
More than a hundred speakers are expected for this new edition with an overview of AI in all its diversity through 5 categories of conferences:
- AI FOR SOCIETY: understanding the benefits of artificial intelligence for society, the planet, and the challenges that lie ahead.
- AI TODAY AND TOMORROW: explore what AI can do today to imagine what future innovations will bring to society and organizations tomorrow.
- AI STRATEGY: gain key insights to improve your AI strategy and take your business to the next level.
- AI TECHNOLOGY: learn how to make the best use of different AI technologies and train your innovation mindset with high-level speakers.
- AI APPLICATIONS: get an overview of the advances AI can bring to organizations, with focuses on different industries.
Press accreditations
To apply for your accreditation for the WAICF, please contact the PR team at waicf@agence-profile.com.
About the WAICF
The World AI Cannes Festival was born out of the desire to bring together businesses and individuals in Artificial Intelligence. Through a rich and diverse line up, attendees are invited to discover and understand the many ways in which artificial intelligence impacts our daily lives. The World AI Cannes Festival also presents a unique opportunity for businesses to be exposed to innovative ideas, novel information, and new findings. Businesses will be called to showcase their knowledge and experiences as well as to network with leading industry players and decision makers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005434/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom